Global Electroceuticals/Bioelectric Medicine Market Outlook 2030

The global bioelectric medicine market size in 2021 is estimated to be USD 21 billion. The global increase in the prevalence of chronic diseases is an important factor driving market growth. More and more electronic products are used to treat various neurological and cardiac diseases, such as obsessive-compulsive disorder (OCD), Parkinson’s disease, dystonia, essential tremor, epilepsy, and arrhythmias in Alzheimer’s disease, which are promoting The key factor in this market. In addition, the increase in the elderly population at risk of neurological and cardiovascular diseases is a factor that is expected to drive market growth during the forecast period. Bioelectrical medicine combines bioengineering, molecular medicine and neuroscience to develop neurostimulation technology for regulating biological processes in the treatment of diseases. The increasing prevalence of chronic diseases such as heart and nervous system diseases is expected to be a major factor driving market growth. According to the US Centers for Disease Control and Prevention, approximately 610,000 people die from heart disease in the United States each year, of which approximately 370 die from coronary heart disease (CHD).

Therefore, there is a great demand for advanced bioelectric medicine to treat these chronic diseases, which is expected to drive market growth. According to 2017 data from the US Centers for Disease Control and Prevention, cardiovascular disease (CVD) is one of the leading causes of death. In the United States, a quarter of deaths may be caused by cardiovascular disease. Stroke and IC are the leading causes of more than 80% of all cardiovascular disease-related deaths.

In addition, the economic burden of CVD may be around US$1,044 billion by 2030. Increased R&D investment by manufacturers and increasing regulatory approval rates for new electronic drug products are other factors that contribute to the growth of the industry. For example, in December 2018, the InterStim Smart Programmer was used with the InterStim system for sacral neuromodulation therapy. Medtronic created a precedent for sacral nerve regulation and hopes that the enhancement of this product will help the company strengthen its market share.

The government;s strict rules and regulations on the development and manufacturing of medical devices (including implantable cardioverter defibrillators and pacemakers) may hinder the growth of the energy drug market. These devices have undergone rigorous clinical trials before PMA (Pre-Market Approval), resulting in a significant increase in costs incurred by manufacturers. In addition, product recalls are a major challenge facing manufacturers, which may have a negative impact on the growth of the industry.

PRODUCT INFROMATION:

In 2020, the implantable cardioverter defibrillator segment was the segment with the largest revenue, because these products are more widely used in arrhythmia. In addition, an increase in the incidence of cardiac arrest, an increase in the elderly population and advanced product development are expected to drive market growth.

Due to the increasing prevalence of Parkinso;s disease and lifestyle-related diseases (such as obesity and depression), the deep brain stimulator segment is expected to show profitable growth during the forecast period. According to data from the European Parkinsons Disease Association (EPDA), there are approximately 6.3 million Parkinsons disease patients worldwide, of which 1.2 million are in Europe. Due to product advancement and the companys launch of new products, the sacral nerve stimulator part accounts for a large part of the revenue. In August 2018, Nevros new Senza II SNS system was approved by the FDA. This release is expected to help the company expand its product portfolio in the areas of neuromodulation and pain management.

TYPE INFORMATION:

According to the type, the bioelectric medicine market has been subdivided into implantable and non-invasive electrochemical devices. Because these products are widely used to treat arrhythmia, chronic pain, ischemia, depression, tremor and sensorineural hearing loss, implantable electrochemical devices are the highest revenue segment in 2020. Unmet needs of customers.

For example, in August 2018, Biotronik improved the detection and diagnosis of arrhythmia with the MoMe heart monitor designed to increase early detection and diagnosis of arrhythmia. It is expected that the non-invasive electronic drug device segment will experience the highest growth during the study period.

This is due to technological progress and the companys increased R&D investment for the development of innovative products. In addition, in developing countries such as India, China, South Africa and Argentina, increased healthcare awareness and the popularity of electrical products are expected to drive the growth of the industry.

APPLICATION INSIGHTS :

In terms of revenue in 2020, the arrhythmia segment dominated the entire market. This is due to the increasing prevalence of arrhythmia patients, involving the use of implantable cardioverter defibrillators and pacemakers for treatment.

Due to advances in treatment options, such as vagus nerve stimulators, there is a considerable compound annual growth rate during the prognosis period. Companies and research institutions focus on the development of innovative products. For example, in January 2017, Hennepin County Medical Center (HCMC) launched a clinical trial using vagus nerve stimulation to treat brain injury.

Sensorineural hearing loss is another important market segment, accounting for a profitable share of revenue in 2020. The prevalence of hearing loss patients is the main growth driver for this market segment. According to data from the National Institutes of Health, in 2018, nearly one-third of people in the 65-74 age group had hearing loss, and nearly half of the population over 75 had hearing loss.

END USE INFORMATION:

Due to the increasing burden of chronic diseases such as arrhythmia, epilepsys disease, retinitis pigmentosa, chronic pain and depression, and the need for frequent or rare hospitalization, the hospital sector has the highest revenue share. For example, as stated by the World Health Organization, approximately 50 million people in the world suffer from epilepsy.

Due to the increasing number of car accidents and other traumatic injuries, this number is expected to increase in the near future. The increase in population and the development of sanitation infrastructure have stimulated the demand for bioelectric drugs. It is expected that the increase in disposable income and the emergence of advanced medical equipment used to treat different serious diseases will promote the application of electromechanics in hospitals.

Another end-use segment includes research institutions and home care. Due to the increase in R&D investment in new product development, this segment is expected to show a significant compound annual growth rate during the forecast period. In addition, increasing government funding for bioelectric medicine supports market growth. For example, in October 2016, the National Institutes of Health announced an allocation of approximately US$20 million for electro pharmaceutical research.

REGIONAL INFORMATION:

Due to the existence of medical device manufacturers such as Medtronic, Boston Scientific and BIOTRONIK, North America dominates the bioelectric drug industry with the largest revenue share. In addition, the regions highly developed healthcare and the supply of advanced products have driven growth. North America is followed closely by Europe, which accounted for more than 30% of the total market in 2020. The growing demand for innovative medical devices and the existence of large bioelectric drug manufacturers, mainly in Germany, are expected to continue to be important driving forces for the market in Switzerland, the United Kingdom, France, and highly developed healthcare infrastructure. The elderly population in Asian countries such as China and India. In addition, the prevalence of chronic diseases including arrhythmia, Alzheimer;s disease, Parkinson;s disease and epilepsy is increasing in the region, which is expected to promote the adoption of electronic drugs.

MAJOR COMPANIES AND MARKET SHARE PROSPECTS:

The bioelectric medicine market is highly fragmented, with numerous manufacturers. Multinational giants such as Medtronic; Boston Scientific; St. Jude Medical; Cochlear Co., Ltd.; LivaNova PLC; Sonova; Bristol; Second Signal; Nefro Corporation; and electroCore, LLC and small and medium-sized suppliers Shared market.

Leading manufacturers provide a wide range of advanced electronic pharmaceutical products through powerful distribution channels around the world. This leads to fierce competition among manufacturers, which puts a lot of pressure on suppliers’ pricing strategies and is expected to affect profit margins. Maximum profit. Share in departmental revenue.

The development and release of new products helps the company expand its existing product portfolio and geographic reach. For example, in December 2018, ElectroCore Inc received FDA approval for gammaCore for the treatment of cluster headaches. This product is the only drug approved by the FDA to treat this disease.

In addition, in June 2019, Boston Scientific acquired Vertiflex, Inc. The acquired company focuses on minimally invasive technology to help relieve the pain of lumbar spinal stenosis and restore body function. The agreement is expected to strengthen the spinal cord stimulation and radiofrequency ablation product portfolio.

REPORT SEGMENTS COVERED :

This report predicts global, regional, and national revenue growth, and analyzes industry trends in each sub-segment from 2022 to 2030. For the purpose of this research, Kenneth Research has subdivided the global bioelectric medicine market report on the basis of product, type, application, end use and region: Product outlook (revenue, millions of dollars; 2022 to 2030) implant Cardioversion defibrillator, pacemaker, cochlear implant, heart rate stimulator, spinal cord deep brain stimulator, transcutaneous electrical nerve stimulator, sacral nerve stimulator, neurostimulator, and other types of bioelectric drugs. Outlook (revenue, millions of dollars; 2022 to 2030) Years) Implantable electrochemical device Non-invasive electrochemical device application prospects (revenue, millions of dollars; 2022 to 2030) Arrhythmia pain management Sensorineural hearing loss Parkinson’s disease tremor depression refractory depression epilepsy urine Incontinence d-use outlook (income, millions of dollars; 2022 to 2030) Other hospitals.

"

Geography Analysis:

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

• North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
• Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.